The Scottish Haemophilia Forum argued in March 2005 that: "The Skipton Fund arose only as the result of the campaigning in Scotland by the Scottish Haemophilia Forum, the Motion supported by 80 MSPs from all parties, the unanimous support of the 1999-2003 Health Committee of the Scottish Parliament and the decision of the then Health Minister Malcolm Chisholm." Read more about The Scottish Haemophilia Forum argued in March 2005 that: "The Skipton Fund arose only as the result of the campaigning in Scotland by the Scottish Haemophilia Forum, the Motion supported by 80 MSPs from all parties, the unanimous support of the 1999-2003 Health Committee of the Scottish Parliament and the decision of the then Health Minister Malcolm Chisholm."
The definition of when a Stage 2 payment should be given was amended to include the infected person developing B-cell non-Hodgkin's Lymphoma where that had arisen after the person contracted Hepatitis C. Read more about The definition of when a Stage 2 payment should be given was amended to include the infected person developing B-cell non-Hodgkin's Lymphoma where that had arisen after the person contracted Hepatitis C.
To qualify for Skipton Fund payments a person had to have been alive from 1 April 2016 and not be eligible for a Stage 2 payment. Scotland also provided for a Stage 2 payment of £50,000 to be made to a person coinfected with HIV if they had not already received a Stage 2 payment. England and Wales provided a bereavement payment of £10,000 if a contributory factor to the person's death was Hepatitis C (or HIV if coinfected). Read more about To qualify for Skipton Fund payments a person had to have been alive from 1 April 2016 and not be eligible for a Stage 2 payment. Scotland also provided for a Stage 2 payment of £50,000 to be made to a person coinfected with HIV if they had not already received a Stage 2 payment. England and Wales provided a bereavement payment of £10,000 if a contributory factor to the person's death was Hepatitis C (or HIV if coinfected).
The Skipton Appeals Panel would not hear from affected individuals personally. Read more about The Skipton Appeals Panel would not hear from affected individuals personally.
Dr Mary Ramsay of the Health Protection Agency Centre for Infections was asked for advice by Nicholas Fish, acting as secretary to the appeals panel, on the extent to which science and statistics showed that injecting drug use for less than two years was likely to be a cause of an Hepatitis C infection, where the sufferer also had a history of blood transfusion and reported on in March 2007. Read more about Dr Mary Ramsay of the Health Protection Agency Centre for Infections was asked for advice by Nicholas Fish, acting as secretary to the appeals panel, on the extent to which science and statistics showed that injecting drug use for less than two years was likely to be a cause of an Hepatitis C infection, where the sufferer also had a history of blood transfusion and reported on in March 2007.
Dr Hewitt wrote to Keith Foster stating that anti-D immunoglobulin produced in the UK had an "unparalleled safety record with regard to transmission of viruses", but there had been known cases of transmission episodes from anti-D produced outside of the UK including the Irish Transfusion board in the 1970s and early 1980s. These were a different method of manufacture and were intravenous preparations. Read more about Dr Hewitt wrote to Keith Foster stating that anti-D immunoglobulin produced in the UK had an "unparalleled safety record with regard to transmission of viruses", but there had been known cases of transmission episodes from anti-D produced outside of the UK including the Irish Transfusion board in the 1970s and early 1980s. These were a different method of manufacture and were intravenous preparations.
Dr Hewitt wrote to Nicholas Fish about Hepatitis C and intramuscular gamma-globulin and the fact that the transmission of the virus had not been documented with its use, despite more than half of preparations containing detectable HCV RNA. However, the intravenous intramuscular immunoglobulin had caused patients to develop non-A non-B Hepatitis, whereas the intramuscular immunoglobulin had not. Read more about Dr Hewitt wrote to Nicholas Fish about Hepatitis C and intramuscular gamma-globulin and the fact that the transmission of the virus had not been documented with its use, despite more than half of preparations containing detectable HCV RNA. However, the intravenous intramuscular immunoglobulin had caused patients to develop non-A non-B Hepatitis, whereas the intramuscular immunoglobulin had not.
The Fund worked with Professor Thomas to create a model of determining whether a person infected with Hepatitis C had reached stage 2 before dying, as their estate would be entitled to payments. This model estimated the likely speed of progression from infection to cirrhosis, differentiating those also coinfected with HIV. Read more about The Fund worked with Professor Thomas to create a model of determining whether a person infected with Hepatitis C had reached stage 2 before dying, as their estate would be entitled to payments. This model estimated the likely speed of progression from infection to cirrhosis, differentiating those also coinfected with HIV.
Guidance on assessing applications for the £20,000 payment from the Skipton Fund did not include first-hand evidence of the applicant in their definition of evidence, so this could not be used to support an application. There was no opportunity for an applicant who could be considered a natural clearer to explain why they considered that their Hepatitis C infection caused suffering beyond 6 months, and the Fund could not examine evidence on this point. Read more about Guidance on assessing applications for the £20,000 payment from the Skipton Fund did not include first-hand evidence of the applicant in their definition of evidence, so this could not be used to support an application. There was no opportunity for an applicant who could be considered a natural clearer to explain why they considered that their Hepatitis C infection caused suffering beyond 6 months, and the Fund could not examine evidence on this point.
The note of an advisory group meeting on hepatitis recorded that "the experts were asked for their initial thoughts on the medical trigger for the second (higher) payment. It was felt that this should be a recognised stage of the disease, rather than subjective symptoms of illness." Read more about The note of an advisory group meeting on hepatitis recorded that "the experts were asked for their initial thoughts on the medical trigger for the second (higher) payment. It was felt that this should be a recognised stage of the disease, rather than subjective symptoms of illness."